The Lung Cancer SPORE Biostatistics and Informatics Core provides support in the areas of biostatistics,clinical informatics, and bioinformatics to SPORE investigators. This consultative and collaborative supportis designed to increase the speed and efficiency with which lung cancer research is translated from the labto the clinic. The Core is designed to provide support in study design, data management, data analysis,clinical informatics system creation, bioinformatics data management and interpretation. The Biostatisticsgroup assists primarily with study and protocol design, and data analysis and interpretation. TheInformatics group assists with data quality control, data sharing, designing and maintaining the SPOREdatabase that captures clinical, pathologic, and laboratory data into a relational database. This group alsodesigned the barcode system for collection and storage of all samples. The Bioinformatics group assistswith computational evaluations of large databases, especially those created with genomic and proteomicanalysis using gene expression and SNP arrays and proteomic profiles. All Core members participate inpreparation of reports, presentations, and manuscripts. In addition to these services, Core members willcontinue their efforts to develop new approaches to improve the efficiency and outcomes of the process oftranslational research.Biostatistics and Informatics Core members will assist SPORE investigators in the following areas:1. Experimental design. Design of both pre-clinical and clinical experiments that can provide usefulanswers to scientific questions of importance in lung cancer.2. Data collection/storage/retrieval/sharing: Creation and maintenance of a sound and user-friendlyinfrastructure for data collection, storage, quality assurance, retrieval, and sharing in support ofSPORE trials and tissue banking.3. Data analysis and manuscript preparation: Structuring of data analyses to provide clear answers toquestions, and to communicate those findings in reports and papers.4. Translational research methodology: Development and implementation of coherent methods thatimprove the efficiency and effectiveness of research across the wide spectrum from pre-clinicalresearch to clinical studies, including work in the development of better understanding of the causesof lung cancer, early detection of lung cancer, biomarkers of lung cancer risk, and lung cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-14
Application #
7448831
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
14
Fiscal Year
2008
Total Cost
$174,290
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646

Showing the most recent 10 out of 435 publications